An established ex vivo 3D culture platform using patient-derived xenograft (PDX) tumors replicate the anti-tumor efficacy observed in vivo

被引：0
|
作者：
Xu, Xiaoxi
Zhang, Wenna
Xie, Bingying
Bao, Zheng Zheng
Mei, Zhu
Wery, Jean-Pierre
Ning, Jinying
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-609
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
609
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Predicting PARPi sensitivity in patient derived ex vivo 3D tumour cultures
    Basten, S.
    Overkamp, J.
    Herpers, B.
    Yan, K.
    Price, L.
    Vader, W.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E104 - E104
  • [42] EVALUATING THE EFFECTIVENESS OF TARGETED ADC THERAPY IN A PATIENT-DERIVED EX VIVO TUMOROID MODEL, 3D-EX, FOR QUANTITATIVE TUMOR CELL KILLING
    Kreahling, Jenny
    Ehrhart, Jared
    Pabon, Mibel
    Iwanowycz, Stephen
    Pastoor, Tina
    Altiok, Soner
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A372 - A372
  • [43] Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer
    Shuford, Stephen
    Wilhelm, Christine
    Rayner, Melissa
    Elrod, Ashley
    Millard, Melissa
    Mattingly, Christina
    Lotstein, Alina
    Smith, Ashley M.
    Guo, Qi Jin
    O'Donnell, Lauren
    Elder, Jeffrey
    Puls, Larry
    Weroha, S. John
    Hou, Xiaonan
    Zanfagnin, Valentina
    Nick, Alpa
    Stany, Michael P.
    Maxwell, G. Larry
    Conrads, Thomas
    Sood, Anil K.
    Orr, David
    Holmes, Lillia M.
    Gevaert, Matthew
    Crosswell, Howland E.
    DesRochers, Teresa M.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [44] Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer
    Stephen Shuford
    Christine Wilhelm
    Melissa Rayner
    Ashley Elrod
    Melissa Millard
    Christina Mattingly
    Alina Lotstein
    Ashley M. Smith
    Qi Jin Guo
    Lauren O’Donnell
    Jeffrey Elder
    Larry Puls
    S. John Weroha
    Xiaonan Hou
    Valentina Zanfagnin
    Alpa Nick
    Michael P. Stany
    G. Larry Maxwell
    Thomas Conrads
    Anil K. Sood
    David Orr
    Lillia M. Holmes
    Matthew Gevaert
    Howland E. Crosswell
    Teresa M. DesRochers
    Scientific Reports, 9
  • [45] The efficacy of bromodomain inhibitor for multiple drug resistant CRPC using new patient-derived ex vivo models
    Obinata, Daisuke
    Lawrence, Mitchell
    Taylor, Renea
    Sandhu, Shahneen
    Selth, Luke
    Risbridger, Gail
    CANCER SCIENCE, 2018, 109 : 1024 - 1024
  • [46] INTERROGATION OF THE TUMOR IMMUNE MICROENVIRONMENT AND EX VIVO PROFILING OF PD-1 BLOCKADE USING THE 3D-EXPLORE EX VIVO PLATFORM OF FRESH PATIENT TUMOR TISSUE
    Ruedlinger, Brittney
    D'Andrea, Jasmin
    Ehrhart, Jared
    Altiok, Soner
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A170 - A170
  • [47] In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum- resistant ovarian carcinoma patient-derived xenograft models
    Chiappa, Michela
    Guffanti, Federica
    Mengoli, Ilaria
    Ridinger, Maya
    Damia, Giovanna
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Hydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screening
    Fong, Eliza L. S.
    Martinez, Mariane
    Yang, Jun
    Mikos, Antonios G.
    Navone, Nora M.
    Harrington, Daniel A.
    Farach-Carson, Mary C.
    MOLECULAR PHARMACEUTICS, 2014, 11 (07) : 2040 - 2050
  • [49] Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models
    Chen, Hao
    Ye, Qingqing
    Lv, Jing
    Ye, Peng
    Sun, Yun
    Fan, Shuqiong
    Su, Xinying
    Gavine, Paul
    Yin, Xiaolu
    PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (04) : 947 - 955
  • [50] A novel ex vivo 3D tumor organoid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology
    Agrawal, Vijayendra
    Pabon, Mibel
    Page, Melba Marie
    Kreahling, Jenny
    Altiok, Soner
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
12345